ライフサイエンスコーパス: kanamycin

1 typhi) to antibiotics such as ampicillin and kanamycin.

2 comparable to that of commercially available kanamycin.

3 to a reporter gene conferring resistance to kanamycin.

4 ive selection for resistance to bleomycin or kanamycin.

5 to a reporter gene conferring resistance to kanamycin.

6 sosomes in hair cells that were treated with kanamycin.

7 gB promoter were resistant to high levels of kanamycin.

8 from its native promoter were susceptible to kanamycin.

9 d in Escherichia coli by their resistance to kanamycin.

10 uce recombination and so remain resistant to kanamycin.

11 The strain was resistant to isoniazid and kanamycin.

12 formants and germinated on medium containing kanamycin.

13 or and carries a gene encoding resistance to kanamycin.

14 pC expression confers adaptive resistance to kanamycin.

15 ikacin, 99.2% for capreomycin, and 96.4% for kanamycin.

16 ncreased resistance against streptomycin and kanamycin.

17 treated with two antibiotics, ampicillin and kanamycin.

18 mutagenesis and bacterial growth assays with kanamycin.

19 ll enhanced structural stability to APH than kanamycin.

20 5 to 2 mug/ml), amikacin (0.25 to 2 mug/ml), kanamycin (0.25 to 2 mug/ml), capreomycin (0.5 to 4 mug/

21 After unilateral intracochlear injections of kanamycin (1 and 2 weeks), VGLUT1 immunoreactivity (ir)

22 y blocked at 37 degrees C in the presence of kanamycin (100 microgram/ml) or chloramphenicol (200 mic

23 ceftiofur (49%) and, to a lesser extent, to kanamycin (19%), trimethoprim-sulfamethoxazole (17%), an

24 e promoter mutations conferred resistance to kanamycin [5 microg/mL < minimum inhibitory concentratio

25 00% for fluoroquinolones, 92.6% and 100% for kanamycin, 93.9% and 97.4% for capreomycin, and 80% and

26 eotide hairpin library that bind 6'-acylated kanamycin A (1) and 6'-acylated neamine (2) identified b

27 ion by modularly assembling 6'-N-5-hexyonate kanamycin A (K) onto a peptoid backbone.

28 stance to the aminoglycoside (AG) antibiotic kanamycin A (KAN) in Mycobacterium tuberculosis.

29 ucts formed are 4'-(adenosine-5'-phosphoryl)-kanamycin A and 4'-(m-nitrobenzyl phosphoryl)-kanamycin

30 ining 2'-amino substituents, also acetylated kanamycin A and amikacin that contain a 2'-hydroxyl subs

31 t multiamine-containing glycosides including kanamycin A and B, tobramycin, paromomycin, and neomycin

32 Conformations of kanamycin A and ribostamycin were compared to those of o

33 Bound conformations of kanamycin A and ribostamycin, in the active site of the

34 t acetylation takes place on the 6'-amine of kanamycin A and the adenylation on 3''- and 9-hydroxyl g

35 owing unique trends: 5'UNNNC3' loops for the kanamycin A derivative (where N is any nucleotide); 5'UN

36 erivative, and pyrimidine-rich loops for the kanamycin A derivative.

37 the divergent synthesis of three classes of kanamycin A derivatives.

38 a concentration range from 100pM to 1muM and kanamycin A from 10nM to 1mM.

39 B, the derivatives based upon tobramycin and kanamycin A have slightly lower RRE affinities, but bett

40 agnetic resonance analysis of the product of kanamycin A phosphorylation revealed that modification o

41 ons as the acetyltransferase responsible for kanamycin A resistance, a hallmark of extensively drug-r

42 Surprisingly, binding of gentamicin and kanamycin A to the chemically synthesized terminal hairp

43 ied products of both reactions revealed that kanamycin A was modified only at one position.

44 Two conformers of kanamycin A were matched well with the two conformers of

45 lyzed by kanamycin nucleotidyltransferase of kanamycin A with either ATP or m-nitrobenzyl triphosphat

46 nucleotidyltransferase catalyzed reaction of kanamycin A with m-nitrobenzyl triphosphate is 2 orders

47 For three of the aminoglycosides, 6''-azido-kanamycin A, 5-O-(2-azidoethyl)-neamine, and 6''-azido-t

48 uation of derivatives based upon neomycin B, kanamycin A, and tobramycin conjugates of 9-aminoacridin

49 Antibiotic substrates for AAC include kanamycin A, kanamycin B, tobramycin, sisomicin, neomyci

50 Gram-negative APH(3') types Ia and IIa with kanamycin A, neamine, and their respective difluorinated

51 o, binary, and ternary complexes of APH with kanamycin A, neomycin B, and metal-nucleotide.

52 ptamer probes with affinity to ampicillin or kanamycin A, respectively.

53 '' and/or O-6'' positions on the ring III of kanamycin A, show very strong activity as antifungal age

54 f RNA hairpin loops that bind derivatives of kanamycin A, tobramycin, neamine, and neomycin B via two

55 However, kanamycin A, which has a 2'-OH, shows a much smaller dec

56 ives of neomycin B, neamine, tobramycin, and kanamycin A.

57 n the nanomolar range for all substrates but kanamycin A.

58 formers were determined for the enzyme-bound kanamycin A.

59 ucture of the enzyme with bound MgAMPCPP and kanamycin A.

60 anamycin A and 4'-(m-nitrobenzyl phosphoryl)-kanamycin A.

61 es or disappears as compared to the original kanamycin A.

62 unambiguously assigned to the 4' hydroxyl of kanamycin A; thus, the products formed are 4'-(adenosine

63 ted with the htk gene encoding a heat-stable kanamycin adenyltransferase.

64 cumulate in vesicles 27 h after the start of kanamycin administration.

65 ies, including antibiotics of ampicillin and kanamycin, alcohols of ethanol and n-butanol and heavy m

66 biotics, including gentamicin, streptomycin, kanamycin, amikacin, and paromomycin, have no effect on

67 sed, a cleavable conjugate of the antibiotic kanamycin and a nonmembrane lytic, broad-spectrum antimi

68 The aminoglycosides kanamycin and amikacin are important bactericidal drugs

69 esistant to kanamycin and those resistant to kanamycin and amikacin.

70 ctive, whilst AMR bacteria to carbenicillin, kanamycin and both two antibiotics were 35 +/- 5%, 28 +/

71 In this report, we examined the effects of kanamycin and chloramphenicol, inhibitors of protein syn

72 3, on guinea pig ears deafened systemically (kanamycin and furosemide) or locally (neomycin).

73 The event recovery rates for nptII/kanamycin and hpt/hygromycin systems were 2.88 and 2.47%

74 llin), quinolone (enoxacin), aminoglycoside (kanamycin and neomycin), and polykeptide (tetracycline)

75 Transductants are selected with kanamycin and screened for loss of the mutant phenotype

76 nation with an allele of oppD interrupted by kanamycin and streptomycin resistance markers.

77 For kanamycin and streptomycin, molecular DST significantly

78 aminoglycosides streptomycin, amikacin, and kanamycin and the cyclic polypeptide capreomycin are all

79 BALB /c.D2(NrampG169) mice were treated with kanamycin and then infected with wild-type or mutant Sal

80 ions should distinguish strains resistant to kanamycin and those resistant to kanamycin and amikacin.

81 system to deliver both a selectable marker (kanamycin) and an Escherichia coli plasmid origin of rep

82 ble markers (ampicillin, chloramphenicol, or kanamycin), and a single FRT site.

83 rA (fluoroquinolones), rrs and eis promoter (kanamycin), and rrs (capreomycin and amikacin).

84 nce to phage infection and to the antibiotic kanamycin, and an inability to form biofilms.

85 taining lethal concentrations of rifampicin, kanamycin, and nalidixic acid.

86 how that aminoglycoside antibiotics, such as kanamycin, and polyamines impinge upon this circuit.

87 cadmium, bacitracin, macrolides, penicillin, kanamycin, and streptothricin, although all isolates wer

88 the MICs of amikacin, gentamicin, neomycin, kanamycin, and tobramycin by a factor of two to eight, a

89 e, we summarized optical and electrochemical kanamycin aptasensors and focuses on recent advances and

90 detection and quantitative determination of kanamycin are needed.

91 we report the design and synthesis of seven kanamycin B (KANB) derivatives.

92 cheme inspired the synthesis of a library of kanamycin B analogues alkylated at various hydroxyl grou

93 the synthesis and antibacterial assay of new kanamycin B analogues.

94 3-, and 2'-amino groups of both neomycin and kanamycin B as being critical functionalities for bindin

95 Neomycin B and kanamycin B bind to pre-tRNAAsp with a Kd value that is

96 s residue partially restoring sensitivity to kanamycin B but not to neomycin.

97 t of an octyl group at the O-4'' position of kanamycin B converts this antibacterial aminoglycoside i

98 ubstituted 2-deoxystreptamine aminoglycoside kanamycin B led to improved selectivity for inhibition o

99 nd that the 3''-NH2 and 6''-OH groups of the kanamycin B parent molecule are not essential for antifu

100 Landscape analysis reveals that kanamycin B stabilizes a non-native, idiosyncratic confo

101 residue is more important for recognition of kanamycin B than neomycin, with mutation of this residue

102 the aminoglycoside antibiotics neomycin and kanamycin B to APH(3')-IIIa (an antibiotic phosphorylati

103 ydroxyl group replacing the 3''-NH2 group of kanamycin B was synthesized.

104 otic substrates for AAC include kanamycin A, kanamycin B, tobramycin, sisomicin, neomycin B, paromomy

105 restores sensitivity to neomycin but not to kanamycin B, with the origins of this differential effec

106 ach, 20 small libraries comprising 100 novel kanamycin-B derivatives have been prepared and evaluated

107 ity of ANT(2'') to confer resistance against kanamycins but not neomycins.

108 e of reviving clinically obsolete drugs like kanamycin by simple chemical modification and an alterna

109 valuated during a repeated administration of kanamycin by two methods.

110 ifampin, streptomycin, ethambutol, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethiona

111 ifampin, ethambutol, streptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethiona

112 the organism was disrupted by insertion of a kanamycin cassette by homologous recombination.

113 ding the second ORF by insertion of an Omega kanamycin cassette, and isogenic strains were constructe

114 h the alo gene was deleted and replaced by a kanamycin cassette, secreted barely detectable hemolytic

115 hleomycin, bleomycin, capreomycin, amikacin, kanamycin, cetylpyridinium chloride, and several sulfa d

116 rt to optimize the antibacterial activity of kanamycin class aminoglycoside antibiotics, we have acco

117 new strategy for structural modifications of kanamycin class aminoglycosides is suggested.

118 aled a break at 30 degrees C only in the APH-kanamycin complex in spectra collected between 21 degree

119 reak at 30 degrees C was observed in the APH-kanamycin complex yielding DeltaCp values of -0.7 kcal x

120 ession and to further test lines selected on kanamycin-containing medium.

121 These new amphiphilic kanamycin derivatives bearing alkyl chains length of 4,

122 The antibacterial effect of the synthesized kanamycin derivatives declines or disappears as compared

123 es and modern techniques in aptasensor-based kanamycin detection techniques in order to provide reade

124 erial flora was manipulated, the addition of kanamycin did not affect the survival of Ent.

125 lycoside antibiotics, such as gentamicin and kanamycin, directly target the ribosome, yet the mechani

126 Pase-filled vesicles increased with repeated kanamycin doses.

127 DST for rifampin and kanamycin from sputum samples yielded results after 12 h

128 ors that use resistance to nourseothricin or kanamycin/G418 to select for propagation in prototrophic

129 he copA gene was disrupted by insertion of a kanamycin gene through homologous recombination.

130 tructed by insertional inactivation with the kanamycin gene.

131 ce were exposed to a mixture of antibiotics (kanamycin, gentamicin, colistin, metronidazole, and vanc

132 e were subject to oral gavage with high dose kanamycin, gentamicin, colistin, metronidazole, vancomyc

133 ng assay to how that streptomycin, neomycin, kanamycin, gentamycin, and hygromycin B trigger conforma

134 tes and in liquid media for aminoglycosides (kanamycin, gentamycin, sisomycin, amikacin, spectinomyci

135 Kinetic studies show that kanamycin group aminoglycosides have higher k(cat) value

136 and 10 y (rpoB D435G [rifampicin]; rrs 1400 [kanamycin]; gyrA A90V [ofloxacin]; 1995 [95% HPD: 1988-1

137 Aminoglycoside antibiotics, such as kanamycin, have ototoxic side effects, which often resul

138 al protein Eis responsible for resistance to kanamycin in a significant fraction of kanamycin-resista

139 ous techniques have been developed to detect kanamycin in biological samples.

140 compound 23 outperformed both vancomycin and kanamycin in reducing the intracellular burden of both G

141 usly used coumermycin A(1), erythromycin and kanamycin in these studies.

142 le medications: amikacin, clarithromycin, or kanamycin, in addition to isoniazid and rifampin.

143 In rats deafened by daily kanamycin injections (from P8 to P16), surviving inner h

144 Rats were given daily kanamycin injections from P8 to P16 to destroy hair cell

145 This strain contains a kanamycin insertion element in the chromosomal copy of l

146 An isogenic strain bearing a kanamycin insertion in mtaR was attenuated for survival

147 tains both an in-frame deletion of cdh and a kanamycin insertion mutation in lpxH, covered by pKJB5.

148 Resistance to the aminoglycoside kanamycin is a hallmark of XDR-TB.

149 Resistance to amikacin (AMK) and kanamycin (KAN) in clinical Mycobacterium tuberculosis s

150 acin (MOX), ofloxacin (OFX), amikacin (AMK), kanamycin (KAN), and capreomycin (CAP) using MGIT 960 an

151 ron added resistance to gentamicin (Gen) and kanamycin (Kan).

152 oroquinolone (FQ) drugs, amikacin (AMK), and kanamycin (KAN).

153 , clofazimine [CFZ], pyrazinamide [PZA], and kanamycin [KAN]) were quantified.

154 omallei include genes encoding resistance to kanamycin (Km), gentamicin (Gm), and zeocin (Zeo); howev

155 lysosomes paralleled those in intracellular kanamycin levels.

156 .5), levofloxacin (<=1.0), amikacin (<=2.0), kanamycin (<=8.0), capreomycin (<=4.0), clofazimine (<=0

157 Experiments that used a kanamycin-marked Stx2 prophage demonstrated that ciprofl

158 nsertional inactivation of ORF1 with a polar kanamycin marker completely abolished urease activity an

159 nical isolates determined to be resistant to kanamycin may not be cross-resistant to amikacin, as is

160 drug resistance to pyrazinamide, ethambutol, kanamycin, moxifloxacin, ethionamide, or clofazimine.

161 red by selection for spectinomycin (aadA) or kanamycin (neo) resistance genes.

162 Enoxacin, kanamycin, neomycin, and tetracycline show synergistic g

163 Kanamycin nucleotidyltransferase [ANT (4',4' ')-I] from

164 The kanamycin nucleotidyltransferase catalyzed reaction of k

165 tate structure for the reaction catalyzed by kanamycin nucleotidyltransferase has been determined fro

166 egiospecificity of the reaction catalyzed by kanamycin nucleotidyltransferase of kanamycin A with eit

167 glutamine synthetase adenylyltransferase or kanamycin nucleotidyltransferase, but provides the compl

168 nitrobenzyl triphosphate, a new substrate of kanamycin nucleotidyltransferase, is reported.

169 We also did this for isoniazid, kanamycin, ofloxacin, rifampicin, and streptomycin resis

170 ed FPs) in two different binary plasmids for kanamycin or glufosinate selection, respectively, to all

171 ors that confer resistance to the antibiotic kanamycin or the herbicide glufosinate have been used to

172 olone (OR, 3.99 [95% CI, 1.10 to 14.40]) and kanamycin (OR, 5.47 [95% CI, 1.64 to 18.24]) resistance

173 fluoroquinolone, and at least 1 of amikacin, kanamycin, or capreomycin based on drug susceptibility t

174 ion with mycobacteria by using RIVET, with a kanamycin preselection and a sucrose postselection.

175 esistance within artificial microbiota under kanamycin pressures.

176 diarrhea for Salmonella colitis, we infected kanamycin-pretreated interleukin 8R (IL-8R) mutant mice

177 active hpyIIRM cassette [containing a 1.4 kb kanamycin resistance (aphA) marker], whether such acquis

178 rless chloramphenicol resistance (Cm(r)) and kanamycin resistance (Km(r)) cassettes, respectively, th

179 gI fragment within lob-2A was deleted, and a kanamycin resistance (Km(r)) gene was inserted into this

180 A spontaneous kanamycin resistance and capreomycin resistance mutation

181 resistance gene may encode spectinomycin or kanamycin resistance based on the expression of aadA or

182 he inactivation of sll0088 by insertion of a kanamycin resistance cartridge in the primary C14S(PsaC)

183 The insertion of a kanamycin resistance cartridge into cbbL resulted in a p

184 A kanamycin resistance cassette (Kan(r)) was inserted into

185 ing sequence was removed and replaced with a kanamycin resistance cassette flanked by two res sites f

186 cells, and disruption of the oapA gene with kanamycin resistance cassette insertion resulted in a si

187 BBA74 was disrupted by the insertion of a kanamycin resistance cassette into the coding region.

188 Replacement of GSU1501 with a kanamycin resistance cassette produced a similarly defec

189 nC mutant generated by introducing an aphA-3 kanamycin resistance cassette produced CPS with no O-ace

190 An in-frame replacement of eptB with a kanamycin resistance cassette rendered E. coli WBB06 (bu

191 rferi B31 by replacing the BBK32 gene with a kanamycin resistance cassette through homologous recombi

192 strain Ec1a (O1:K1:H7) were replaced with a kanamycin resistance cassette to produce an oxyRS mutant

193 y of phiBB-1 to package and transduce DNA, a kanamycin resistance cassette was inserted into a cloned

194 Afterwards, the kanamycin resistance cassette was removed from each muta

195 of R. leguminosarum was created by placing a kanamycin resistance cassette within acpXL, the gene whi

196 g rifampin resistance) or a large insertion (kanamycin resistance cassette).

197 d by insertional inactivation of plcR by the kanamycin resistance cassette, aphA3.

198 r hypB (HypB:kan) have been interrupted by a kanamycin resistance cassette.

199 subcloned and mutagenized by insertion of a kanamycin resistance cassette.

200 ent strain was constructed by insertion of a kanamycin resistance determinant within the ureC gene vi

201 (encoded by ssrA), coupled with a multicopy kanamycin resistance determinant, suppressed both lon ph

202 nstructed in this gene by the insertion of a kanamycin resistance DNA cassette into the chromosome.

203 the corresponding gene was disrupted with a kanamycin resistance gene (aphA3) in H. pylori ATCC 4350

204 A kanamycin resistance gene (kan) was introduced into B. b

205 eliloti gltA gene was mutated by inserting a kanamycin resistance gene and then using homologous reco

206 train, E. coli O157:H7 W6-13, by inserting a kanamycin resistance gene cassette (kan) into wcaD and w

207 mutant, which was created by insertion of a kanamycin resistance gene cassette at the 5' region of i

208 e K8.1 open reading frame and insertion of a kanamycin resistance gene cassette within the K8.1 gene.

209 344 (SL1344 trxA), replacing the gene with a kanamycin resistance gene cassette.

210 tions of the transposon Tn5 or Tn3-nice or a kanamycin resistance gene in each of these genes abolish

211 The MDV US3 orthologue was replaced with a kanamycin resistance gene in the infectious bacterial ar

212 nalysis revealed there was an insertion of a kanamycin resistance gene in the lgt2 gene of D4, which

213 e vectors into a plasmid containing a mutant kanamycin resistance gene in vitro.

214 ted DBB25, was constructed by insertion of a kanamycin resistance gene into alcA, one of the genes es

215 d one of these fragments hybridized with the kanamycin resistance gene of the plasmid vector.

216 ucted loxP511 transposons contained either a kanamycin resistance gene or no marker.

217 disrupted in strain 81-176 by insertion of a kanamycin resistance gene through homologous recombinati

218 LEU2 genes and a transposon-derived neomycin/kanamycin resistance gene were successfully expressed fr

219 es a gC-negative deletion mutant harboring a kanamycin resistance gene, a markerless mutant with the

220 of pDMG21A, a pVT745 derivative containing a kanamycin resistance gene, displayed a structural rearra

221 pJGS84, a derivative of pAP1 containing a kanamycin resistance gene, was able to replicate in Esch

222 onstructed by replacing the mazG gene with a kanamycin resistance gene.

223 der gene (originally annotated yfgK) with a kanamycin resistance gene.

224 plasmids containing mariner transposons and kanamycin resistance genes expressible in B. burgdorferi

225 ssette was designed so that the luxABCDE and kanamycin resistance genes were linked to form a single

226 gulated expression for the LEU2 and neomycin/kanamycin resistance genes.

227 mined in this study that exhibited low-level kanamycin resistance harbored eis promoter mutations.

228 antify the static and dynamic composition of kanamycin resistance in artificial microbiota to evaluat

229 plication origin, the nptIII gene conferring kanamycin resistance in bacteria, both the right and lef

230 The kanamycin resistance marker allows efficient direct sele

231 laced in a binary plasmid vectorcontaining a kanamycin resistance marker and a cauliflower mosaic vir

232 nstructs of fbpA and fbpB disrupted with the kanamycin resistance marker OmegaKm and containing varyi

233 omposite transposons containing IS6110 and a kanamycin resistance marker were constructed.

234 These mutations restored high levels of kanamycin resistance not through an improvement in the p

235 Bioluminescence and kanamycin resistance only occur in a bacterial cell if t

236 with both approaches using attP vectors with kanamycin resistance or spectinomycin resistance as the

237 the ability of these heterodimers to confer kanamycin resistance to Escherichia coli cells was impai

238 hotransferase type II gene, which can confer kanamycin resistance to transgenic plants, represent an

239 The mutations R177S and V198E restored the kanamycin resistance to wild-type levels while maintaini

240 d a genetic selection for splicing-dependent kanamycin resistance with no significant bias when six a

241 model successfully predicted the dynamics of kanamycin resistance within artificial microbiota under

242 The transposon introduces both positive (kanamycin resistance) and negative (I-SceI recognition s

243 cillin resistance), aphA1-Iab (which encodes kanamycin resistance), strA and strB (which encode strep

244 rom pUC21 (ampicillin resistance) and pUK21 (kanamycin resistance).

245 The loxP sites flank npt, conferring kanamycin resistance, and sacB, which confers sensitivit

246 s to the stable phenotypes of tumorigenesis, kanamycin resistance, and stable beta-glucuronidase (GUS

247 ulting MS17 clone possessed erythromycin and kanamycin resistance, flat-wave morphology, and microsco

248 cation, and genes for rare transfer RNAs and kanamycin resistance.

249 utonomously replicating plasmid that confers kanamycin resistance.

250 hia coli-H. pylori shuttle vector conferring kanamycin resistance.

251 is, which increase its expression and confer kanamycin resistance.

252 Genetic analysis of the kanamycin-resistance (KanR) trait in >900 independent tr

253 nsion, was interrupted by the insertion of a kanamycin-resistance cassette between the ferrochelatase

254 optional chloramphenicol-, tetracycline-, or kanamycin-resistance cassettes.

255 plants transformed with a vector containing kanamycin-resistance gene (npt) flanked by FRT sites, wh

256 nd negative selection markers, which are the Kanamycin-resistance gene, the sacB gene and temperature

257 When used in tandem with a kanamycin-resistance marker, the cassette was successful

258 that suffers mutations during acquisition of kanamycin-resistance results in an overwhelming majority

259 nce of AID and a genetic reversion assay for kanamycin-resistance to investigate the causes of multip

260 ecreasing C. jejuni colonization by means of kanamycin resistant strain compared to the control group

261 lementation of a B. burgdorferi B31 A3 BBK32 kanamycin-resistant (B31 A3 BBK32::Kan(r)) mutant, defic

262 ites were amplified by PCR and cloned into a kanamycin-resistant (Kan(r)) suicide vector.

263 In contrast, a fraction of kanamycin-resistant (Km(r)) and nalidixic acid-resistant

264 tted us to generate hundreds of erythromycin/kanamycin-resistant B. burgdorferi clones with each of t

265 previously described nonmotile, rod-shaped, kanamycin-resistant B. burgdorferi flaB::Km null mutant

266 DNA sequencing of several kanamycin-resistant clones generated with one of the sui

267 mediated by electroporation of pJM6 produced kanamycin-resistant clones that were not reactive with M

268 s that contained both lp25 and lp56; the few kanamycin-resistant colonies isolated did not contain pB

269 air activity, evidenced by the appearance of kanamycin-resistant colonies.

270 After 1 month, the mice were challenged with kanamycin-resistant M. avium 104.

271 ce to kanamycin in a significant fraction of kanamycin-resistant Mycobacterium tuberculosis clinical

272 posed to a 48 h microaerobic shock generated kanamycin-resistant papillae after only 6-14 days.

273 Under normal atmospheric conditions, kanamycin-resistant papillae appeared after only about 5

274 lambda phage transduction and selecting for kanamycin-resistant recombinants.

275 After a dose of oral kanamycin, Salmonella-infected congenic BALB/c.D2(NrampG

276 nts were identified by PCR and compared with kanamycin-selected transformants from the same T(1) seed

277 is B surface antigen and a gene encoding the kanamycin selection marker.

278 lus sinicus by Agrobacterium rhizogenes with kanamycin selection.

279 erichia coli when a carbenicillin, but not a kanamycin, selection marker was used.

280 These kanamycin-sensitive mutants were used as recipients in f

281 eed, the observed 330% gain we observe for a kanamycin sensor is 2-fold greater than that seen on pla

282 resistance of host cells to the antibiotics kanamycin, spectinomycin, and nourseothricin.

283 terobacter cloacae (conferring resistance to kanamycin, spectinomycin, lincomycin, and gentamycin/sis

284 h specificity over other antibiotics such as kanamycin, streptomycin, ciprofloxacin, and tetracycline

285 The second was resistance to ampicillin, kanamycin, streptomycin, sulfamethoxazole, and tetracycl

286 ant, with distinct resistance to ampicillin, kanamycin, streptomycin, sulfamethoxazole, and tetracycl

287 re able to monitor varying concentrations of kanamycin sulfate as low as ~100 picogram/L.

288 rast, the lowest detectable concentration of kanamycin sulfate on silicon without any metallic struct

289 d trace amounts of molecules of antibiotics (kanamycin sulfate) dispersed on metasurfaces with terahe

290 were grown at the permissive temperature on kanamycin-supplemented agar and subsequently prevented f

291 Single i.p. doses of gentamicin or kanamycin suppressed SOAEs below 2.6 kHz, while modulati

292 microbes, and for differentiating between a kanamycin susceptible and resistant strain.

293 Kanamycin therapy may thus select for mutants with incre

294 solates harboring eis mutations, selected by kanamycin therapy, which may drive the expansion of stra

295 This approach allows kanamycin to enter mammalian cells as a conjugate linked

296 Binding of kanamycins to APH occurs with a larger negative DeltaH i

297 5 strain was mutagenized with a mini-Tn5 Km (kanamycin) transposon, and mutants were tested for the a

298 dators) and bacteria (competitors), and (ii) kanamycin treatment to reduce competition from indigenou

299 infection over 6 h and its regression after kanamycin treatment were visualized by whole-body imagin

300 is of immunogold staining revealed that: (1) kanamycin was primarily localized in vesicles beneath th